REYON PHARMACEUTICAL CO., LTD (이연제약(주))
KOSPI Stock Code: 102460 | DART Corp Code: 00145598
English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.
| English name (as registered with DART) | REYON PHARMACEUTICAL CO., LTD |
|---|---|
| Korean legal name | 이연제약(주) |
| Alternate names | 이연제약 |
| Market | KOSPI |
| Stock Code | 102460 |
| DART Corp Code | 00145598 |
| CEO | 정순옥, 유용환 (각자 대표이사) |
| Business Registration No. | 1068100516 |
| Corporate Registration No. | 1101110048143 |
| Established Date | 1964-11-25 |
| Fiscal Month | 12 |
| KSIC Industry Code | 212 |
| Address (KO) | 서울특별시 강남구 테헤란로 620 에이동 12층 (대치동, 미래에셋타워) |
| Homepage | https://reyonpharm.co.kr/ |
| source_url | https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260320001314 |
| verified_at | 2026-11-01T02:19:45.043Z |
Annual Financial Summary (KRW)
Fiscal Year: 2025 | Basis: CFS (Consolidated) | Currency: KRW | Filing Source: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260320001314
| Account | FY2025 (Current) | FY2024 (Prior) |
|---|---|---|
| Revenue (매출액) | KRW 145,928,626,140 | KRW 148,299,673,635 |
| Operating Income (영업이익) | KRW -30,268,572,134 | KRW 79,259,194 |
| Net Income (당기순이익) | KRW -29,633,118,376 | KRW 4,151,240,203 |
| Total Assets (자산총계) | KRW 465,099,644,104 | KRW 499,993,817,147 |
| Total Liabilities (부채총계) | KRW 244,826,766,579 | KRW 250,052,738,249 |
| Total Equity (자본총계) | KRW 220,272,877,525 | KRW 249,941,078,898 |
Recent DART Filings (Last 90 Days, up to 20)
| Filed Date | Receipt No. | English Title | Korean Title | Filer |
|---|---|---|---|---|
2026-10-28 | 20261028800573 | Results of issuance (Voluntary Disclosure) | 유상증자또는주식관련사채등의발행결과(자율공시) | 이연제약 |
2026-10-27 | 20261027000356 | [Corrected description]Decision on Issuance of Convertible Bonds | [기재정정]주요사항보고서(전환사채권발행결정) | 이연제약 |
2026-10-26 | 20261026000297 | Report on Major Issues (Decision on Acquisition of Treasury Convertible Bonds before Maturity) | 주요사항보고서(자기전환사채만기전취득결정) | 이연제약 |
2026-10-26 | 20261026800475 | Adjustments of Conversion Price, Warrant Exercise Price or Exchange Price (Information Disclosure) | 전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시) | 이연제약 |
2026-10-20 | 20261020000373 | Report on significant holdings of stocks, etc. (Short form) | 주식등의대량보유상황보고서(약식) | 지브이에이자산운용 |
2026-10-16 | 20261016800511 | Adjustments of Conversion Price, Warrant Exercise Price or Exchange Price (Information Disclosure) | 전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시) | 이연제약 |
2026-10-16 | 20261016800473 | Results of issuance (Voluntary Disclosure) | 유상증자또는주식관련사채등의발행결과(자율공시) | 이연제약 |
2026-10-13 | 20261013000057 | [Corrected description]Decision on Issuance of Convertible Bonds | [기재정정]주요사항보고서(전환사채권발행결정) | 이연제약 |
2026-10-08 | 20261008000695 | Decision on Issuance of Convertible Bonds | 주요사항보고서(전환사채권발행결정) | 이연제약 |
2026-10-08 | 20261008000687 | Decision on Issuance of Convertible Bonds | 주요사항보고서(전환사채권발행결정) | 이연제약 |
2026-10-08 | 20261008000597 | Report on significant holdings of stocks, etc. (General) | 주식등의대량보유상황보고서(일반) | 정순옥 |
2026-09-28 | 20260928800635 | Report on Shares Change of Largest Shareholders | 최대주주등소유주식변동신고서 | 이연제약 |
2026-09-28 | 20260928000328 | Report on significant holdings of stocks, etc. (General) | 주식등의대량보유상황보고서(일반) | 정순옥 |
2026-09-28 | 20260928000281 | Report on Major Issues (Decision on Acquisition of Treasury Convertible Bonds before Maturity) | 주요사항보고서(자기전환사채만기전취득결정) | 이연제약 |
2026-08-14 | 20260814004092 | Semi-annual Report (2026.06) | 반기보고서 (2026.06) | 이연제약 |
Source & Disclaimer
source_url: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260320001314 | verified_at: 2026-11-01T02:19:45.043Z
Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.